SH-PTP2 Activators
The chemical class denoted as SH-PTP2 Activators are a set of compounds orchestrated to intricately modulate and amplify the functional activity of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SH-PTP2). Within this ensemble, Erlotinib and Dasatinib emerge as architects of sustained SH-PTP2 activation, disrupting negative feedback loops that might otherwise curtail its activity. Their mechanisms intricately navigate cellular signaling, ensuring the perpetuation of SH-PTP2's catalytic prowess. In a parallel modulatory vein, Calyculin A and PP2 navigate indirect routes, influencing SH-PTP2 by targeting protein phosphatases and Src kinases, respectively. These compounds engage in a nuanced interplay with the intricate network of cellular signaling, indirectly sculpting the landscape for heightened SH-PTP2 activity. ATRA, on the other hand, emerges as a regulator of SH-PTP2 expression. By elevating SH-PTP2 levels, ATRA orchestrates a cascade effect, amplifying the phosphatase's activity and subsequently impacting downstream cellular processes.
The interplay extends further to Forskolin and Wortmannin, which orchestrate their effects through the cAMP and PI3K pathways, respectively. These compounds, with precision akin to molecular conductors, indirectly bolster SH-PTP2 activation, highlighting the complexity of signaling cascades interwoven in the modulation of SH-PTP2. The ensemble reaches its zenith with Bisindolylmaleimide I and NSC 87877, which directly engage with SH-PTP2's phosphatase activity. These compounds act as direct facilitators, ensuring enhanced access to substrates for SH-PTP2, thereby directly influencing its catalytic function. Expanding the repertoire, Staurosporine and SB203580 broaden their scope, impacting broader cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, a tyrosine kinase inhibitor, acts on the EGFR pathway. It enhances SH-PTP2 activity by preventing EGFR autophosphorylation, promoting SH-PTP2 binding and subsequent dephosphorylation, resulting in increased SH-PTP2 activation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src kinase inhibitor that indirectly enhances SH-PTP2 activity. By inhibiting Src, it interrupts the negative feedback loop on SH-PTP2, allowing sustained activation of SH-PTP2. This results in amplified downstream signaling cascades through SH-PTP2 involvement. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000B sc-24000C | 10 µg 100 µg 500 µg 1 mg | $160.00 $750.00 $1400.00 $3000.00 | 59 | |
Calyculin A is a protein phosphatase inhibitor, specifically targeting PP1 and PP2A. By inhibiting SH-PTP2 dephosphorylation, Calyculin A increases SH-PTP2 phosphorylation and enhances its activity, leading to augmented downstream signaling through the MAPK pathway. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
All-trans retinoic acid (ATRA) modulates SH-PTP2 indirectly by affecting its expression. ATRA promotes SH-PTP2 gene transcription, leading to an increase in SH-PTP2 protein levels. Elevated SH-PTP2 levels enhance its phosphatase activity, intensifying signaling cascades involving SH-PTP2. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2, a Src family kinase inhibitor, indirectly activates SH-PTP2 by disrupting the negative feedback loop. Inhibition of Src by PP2 prevents its inhibitory phosphorylation of SH-PTP2, resulting in prolonged SH-PTP2 activation and potentiation of downstream signaling events. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels. Elevated cAMP enhances SH-PTP2 expression through the cAMP-response element binding protein (CREB). The upregulation of SH-PTP2 levels amplifies its activity, intensifying cellular responses mediated by SH-PTP2. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, a PKC inhibitor, indirectly activates SH-PTP2 by preventing its PKC-mediated inhibitory phosphorylation. In the absence of PKC inhibition, SH-PTP2 remains unphosphorylated, ensuring sustained phosphatase activity and heightened downstream signaling cascades. | ||||||
NSC 87877 | 56990-57-9 | sc-204139 | 50 mg | $134.00 | 12 | |
NSC 87877, a PTP inhibitor, directly enhances SH-PTP2 activity by inhibiting other phosphatases. By competing for substrate binding, NSC 87877 ensures increased access of SH-PTP2 to its substrates, resulting in augmented dephosphorylation and activation of downstream signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly activates SH-PTP2 by blocking the PI3K pathway. Inhibition of PI3K relieves the negative regulation on SH-PTP2, allowing sustained activation. This leads to enhanced SH-PTP2 phosphatase activity and potentiation of downstream signaling events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly activates SH-PTP2 by modulating MAPK signaling. Inhibition of p38 MAPK relieves the suppressive effect on SH-PTP2, leading to increased SH-PTP2 activity. This results in amplified downstream signaling cascades through the MAPK pathway. | ||||||